A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Phase 2 Completed 62 enrolled Dr Anders Ullén

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aim to compare the efficacy, safety and quality of life of vinflunine/gemcitabine and carboplatin/gemcitabine in patients with metastatic urothelial cancer and impaired renal function.

Timeline

Start: 2014-04
Primary completion: 2018-09
Completion: 2018-09

Publications

Holmsten K, Jensen NV, Mouritsen LS, Jonsson E, Mellnert C, Agerbaek M, Nilsson C, Moe M, Carus A, Ofverholm E, Lahdenpera O, Brandberg Y, Johansson H, Hellstrom M, Maase HV, Pappot H, Ullen A. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). Eur J Cancer. 2020 Mar;127:173-182. doi: 10.1016/j.ejca.2019.08.033. Epub 2019 Oct 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Carboplatin	Small molecule	4.5 unknown	Intravenous
Subject	Vinflunine	Small molecule	250 mg/m2	Intravenous
Subject	Vinflunine	Small molecule	280 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Summary

Timeline

Publications

Drugs

Indications